Suchergebnisse - "Cook, Gordon"

PubPharm (34)

1

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

2

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

enthalten in: EClinicalMedicine | 2023

von Jones, J. | Cairns, D. | Menzies, T. | +15

3

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

4

Optimizing the value of lenalidomide maintenance by extended genetic profiling : an analysis of 556 patients in the Myeloma XI trial

enthalten in: Blood | 2023

von Panopoulou, A. | Cairns, D. | Holroyd, A. | +13

CommentIn: Blood. 2023 Apr 6;141(14):1649-1650. - PMID 37022733

5

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma : Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von de Tute, R. | Pawlyn, C. | Cairns, D. | +14

CommentIn: J Clin Oncol. 2022 Sep 1;40(25):2863-2866. - PMID 35772041

6

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)) : a study protocol for a randomised phase III trial

enthalten in: BMJ open | 2022

von Coulson, A. | Royle, K. | Pawlyn, C. | +22

CommentIn: Lancet Healthy Longev. 2022 Nov;3(11):e729-e730. - PMID 36356621

7

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

8

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

9

Ixazomib-lenalidomide-dexamethasone in routine clinical practice : effectiveness in relapsed/refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2021

von Hájek, R. | Minařík, J. | Straub, J. | +33

10

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15